DPHARM Idol Presenting Companies Announced to Compete for Most Disruptive New Company in Clinical Trials at DPHARM from the Conference Forum
Summary
Its FDA-cleared platform allows professionals to detect earlier and more accurately, diagnose more confidently, manage treatment effectively, and give patients the best care possible. The AI applies appropriate biostatistics to raw data, and then describes the findings in paragraphs for clinical study reports, abstracts or even posters. Readout AI turbocharges medical writing and biostatistics, shrinking the time to turn raw clinical data into actionable outputs. DPHARM Idol Disrupt 2023 judges are: Esther Dyson, Founder, Wellville Jennifer Levin Carter, MD, MPH, MBA, Venture Partner, Sandbox Industries Cindy Geoghegan, Patient Advocate Yusuf Ghadiali, Executive Director, Global Clinical Operations & Planning, Daiichi Sankyo Bert Hartog, PhD, MSc, Senior Director, Janssen Clinical Innovation, Janssen Research & Development Andrea Jackson, MBA, Director, Northpond Ventures Hassan Kadhim, Head of Clinical Trial Business Capabilities, BMS Sarah Krüg, Executive Director, Cancer 101, CEO, Health Collaboratory Nuwan Kurukulasuriya, PhD, Global Vice President, Medical Affairs, Alexion, AstraZeneca Rare Disease Matt W. Maddox, AVP, Eli Lilly Siân Ratcliffe, PhD, SVP, Head of Global Clinical Operations, Analytics, Technology & Data Sciences, Biogen Doug Schantz, SVP, Clinical Operations, Asklepios BioPharmaceutical Mark Travers, PhD, MBA, VP, Head of GCTO, Regions and Regional Operations, Merck Donna Usiskin, Chief Strategy Officer, New Enterprise Ventures Taylor Uttley, Head of Strategy and Operations, Data Strategy and Solutions, Vertex Pharmaceuticals For more information, please contact [email protected] or visit dpharmconference.com. The concept of DPHARM was founded by Pfizer and Janssen, who continue to play a key role on the steering committee to deliver a highly relevant and engaging program.